ArticleeLife2018
Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Antibody-Based Therapeutic Interventions for Amyotrophic Lateral Sclerosis: A Systematic Literature Review.Frontiers in neuroscience · 2021Pooled it
- Muscle-Specific Kinase Signaling and Its Therapeutic Potential.Muscle & nerve · 2026Review
- Cytoplasmic region of beta-dystroglycan is essential for postsynaptic maturation and neuromuscular function in mice.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Neuromuscular junction innervation and motor function are preserved by restoring muscarinic signaling in perisynaptic glia in ALS.iScience · 2026Article
- Nanotube-Assisted Motor Neuron and Neuromuscular Junction Stabilization in Spinal Muscular Atrophy: A Hypothesis for Adjunctive Therapy.Neurology international · 2026Review
- Review of the Pathology of Muscle in Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2026Review
- Early postsynaptic instability and acetylcholine receptor compartmentalization precede neuromuscular synapse dismantling.Communications biology · 2026Article
- MuSK myasthenia gravis: from antigen-antibody to clinical translation.Frontiers in immunology · 2026Review
- Gene-specific response to muscle specific kinase agonist antibody in the treatment of congenital myasthenic syndromes.Brain communications · 2026Article
- The Neuromuscular Junction: A Shared Vulnerability in Aging and Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Review
- MuSK cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis.The Journal of clinical investigation · 2025Article
- Lymphatic dysfunction correlates with inflammation in a mouse model of amyotrophic lateral sclerosis.Disease models & mechanisms · 2025Article
- Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models.iScience · 2025Article
- Muscle-specific Bet1L knockdown induces neuromuscular denervation, motor neuron degeneration, and motor dysfunction in a rat model of familial ALS.Frontiers in neuroscience · 2025Article
- Article
- Muscle-specific kinase levels in blood are an early diagnostic biomarker for SOD1-93A mouse model of ALS.Frontiers in neurology · 2025Article
- Agonist antibody to MuSK protects mice from MuSK myasthenia gravis.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The MuSK agonist antibody protects the neuromuscular junction and extends the lifespan in C9orf72-ALS mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Building, Breaking, and Repairing Neuromuscular Synapses.Cold Spring Harbor perspectives in biology · 2024Review
- Skeletal muscle in amyotrophic lateral sclerosis.Brain : a journal of neurology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Sarah CantorMolecular Neurobiology Program, Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute of Biomolecular Medicine, NYU Medical School, New York, United States.ORCID http://orcid.org/0000-0002-8675-3729
Wei ZhangMolecular Neurobiology Program, Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute of Biomolecular Medicine, NYU Medical School, New York, United States.
Nicolas DelestréeCenter for Motor Neuron Biology and Disease and Departments of Pathology and Cell Biology and Neurology, Columbia University, New York, United States.
Leonor RemédioMolecular Neurobiology Program, Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute of Biomolecular Medicine, NYU Medical School, New York, United States.ORCID http://orcid.org/0000-0002-1509-0024
George Z MentisCenter for Motor Neuron Biology and Disease and Departments of Pathology and Cell Biology and Neurology, Columbia University, New York, United States.
Steven J BurdenMolecular Neurobiology Program, Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute of Biomolecular Medicine, NYU Medical School, New York, United States.ORCID http://orcid.org/0000-0002-3550-6891
Columbia University · US
Funding
Mechanisms of Central Synaptic Dysfunction in SMAR01NS078375 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI George Z Mentis · 2012 to 2026
$6.6MSignaling by MuSK, a component of the Agrin receptor.R37NS036193 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BURDEN, STEVEN · 2013 to 2019
$4.5MTraining Program in Molecular, Cellular, and Translational NeuroscienceT32NS086750 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JEREMY S DASEN, Katherine Nagel · 2014 to 2026
$2.4MNINDS NIH HHS R01 NS078375NINDS NIH HHS R37 NS036193NINDS NIH HHS R37 NS36193NINDS NIH HHS RO1 NS078375NINDS NIH HHS T32 NS086750NINDS NIH HHS T32 NS86750
Abstract
In amyotrophic lateral sclerosis (ALS) and animal models of ALS, including
Indexed as
Amyotrophic Lateral SclerosisAnimalsAntibodiesDisease Models, AnimalImmunologic FactorsMiceMotor NeuronsNeuromuscular JunctionReceptor Protein-Tyrosine KinasesTreatment OutcomeAntibodiesImmunologic FactorsMuSK protein, mouseReceptor Protein-Tyrosine Kinasesagonist antibodyamyotrophic lateral sclerosismotor neuronmouseMuSKneurodegenerationneuromuscular diseaseneuroscience
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.